TICKERNERD
Menu
NRSNNRSNHealthcare · Biotechnology

NRSN Stock Forecast: Neurosense Therapeutics Ltd. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$1.42

The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. hold a median 12-month price target of $92 — +6361.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.7M
Ticker Nerd rank
3/ 100
Median analyst target
$92
Analysts covering
3
Revenue$0.0
Operating income−$1.8M
Net income−$1.8M
Quarterly, 6 quarters to 31 Dec 2024 · latest quarter's figure shown
Ticker Nerd rank

NRSN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurosense Therapeutics Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
3/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Revisions
32
Volatility
25
Growth
8
Accruals
8
Value
7
Quality
5
Momentum
3
Issuance
0

Size (97): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NRSN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRSN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $4Median $92High $180

The green dot is the last close — the median target sits +6361.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Nov 2026HC Wainwright & Co.DowngradeNeutral—
28 Sept 2026HC Wainwright & Co.MaintainsBuy$8.00 → $52
3 Sept 2026HC Wainwright & Co.InitiatesBuy$8.00
3 Sept 2026HC Wainwright & Co.InitiatesBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy$14
8 Apr 2026D. Boral CapitalMaintainsBuy—
25 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
10 Mar 2026Roth CapitalInitiatesBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
22 Dec 2025D. Boral CapitalMaintainsBuy—
24 Nov 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
10 July 2025D. Boral CapitalMaintainsBuy—
12 May 2025D. Boral CapitalInitiatesBuy—
16 Dec 2024Maxim GroupDowngradeHold—
17 July 2023Alliance Global PartnersInitiatesBuy$7.50
7 Jan 2022Maxim GroupInitiatesBuy$7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NRSN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

NRSN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Neurosense Therapeutics Ltd. (NRSN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
—
EV / EBITDA
−0.2×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−2175.0%

Higher than 1% of US stocks

Return on assets
−247.3%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurosense Therapeutics Ltd. (NRSN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurosense Therapeutics Ltd. has a market value of $2.7M and an enterprise value of $2.5M.

  • Revenue in the twelve months to 31 Dec 2024: $0.0.

  • Net income over the same four quarters: −$10.2M.

  • Shares outstanding: 32.6M.

  • Trailing P/E: −3.2×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neurosense Therapeutics Ltd. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2024 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

NRSN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRSNNeurosense Therapeutics Ltd.$2.7M3
CLDICalidi Biotherapeutics, Inc.$2.7M23
DCOYDecoy Therapeutics, Inc.$2.7M19
VIVSVivoSim Labs, Inc.$2.5M36
EOCNEocene Ltd.$2.9M13
APVOAptevo Therapeutics, Inc.$2.5M27
CMNDClearmind Medicine, Inc.$3.0M6

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurosense Therapeutics Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRSN news & analysis

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

PRNewsWire · 2 Nov 2026positive

NeuroSense Therapeutics plans to add new neurofilament light chain (NfL) analysis to PrimeC’s Canadian ALS submission package. Health Canada confirmed a March 2027 filing timeline; the submission would be PrimeC’s first marketing application in any jurisdiction.

Why it matters — The expanded submission package and confirmed timeline are developments for NRSN watchers tracking PrimeC’s regulatory progress in Canada.

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

PRNewsWire · 29 Oct 2026positive

NeuroSense Therapeutics said it will present integrated clinical and biomarker evidence from the PARADIGM program at NEALS 2026. The presentation will describe how those findings are informing PrimeC’s Phase 3 development strategy for PARAGON.

Why it matters — The update concerns clinical and biomarker evidence guiding the development strategy for NeuroSense’s PrimeC program.

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

PRNewsWire · 19 Oct 2026positive

NeuroSense Therapeutics filed a U.S. patent application seeking protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE). The company said the filing could support expansion beyond ALS and research partnership opportunities.

Why it matters — The application signals a potential development area for PrimeC beyond ALS, though the excerpt describes a filing rather than an approved treatment.

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

PRNewsWire · 13 Oct 2026neutral

NeuroSense said its shares continue to trade on Nasdaq while it awaits a Panel decision, after regaining compliance with the minimum bid price requirement. The company cited a Health Canada New Drug Submission targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027.

Why it matters — The Nasdaq Panel decision and the stated regulatory and funding milestones are developments NRSN watchers may follow.

NeuroSense Provides Update on Nasdaq Listing Compliance

PRNewsWire · 2 Oct 2026positive

NeuroSense Therapeutics Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement.

Why it matters — This update indicates progress on one Nasdaq listing requirement while the company continues working to resolve the remaining minimum market value condition, which is relevant to its continued listing status.

FAQ

Frequently asked questions about NRSN stock

What is the NRSN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. have a median 12-month price target of $92, with estimates ranging from $3.5 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRSN stock a buy right now?

Of the 3 analysts covering Neurosense Therapeutics Ltd., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurosense Therapeutics Ltd. 3 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRSN?

As at 4 Nov 2026, Neurosense Therapeutics Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will NRSN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +6361.3% from the last close, and Ticker Nerd's factor model ranks Neurosense Therapeutics Ltd. 3 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRSN stock forecast for 2030?

No analyst covering Neurosense Therapeutics Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRSN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $180 over the next 12 months.

What does Neurosense Therapeutics Ltd. do?

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases.

What is the latest news on NRSN?

The most recent item we track (PRNewsWire, 2 Nov 2026): "NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data". NeuroSense Therapeutics plans to add new neurofilament light chain (NfL) analysis to PrimeC’s Canadian ALS submission package. Health Canada confirmed a March 2027 filing timeline; the submission would be PrimeC’s first marketing application in any jurisdiction.

Company

About Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is an oral combination therapy designed for amyotrophic lateral sclerosis (ALS), while its broader pipeline includes research programs for Alzheimer’s disease and Parkinson’s disease. The company develops targeted therapeutic approaches intended to address complex neurological conditions with significant unmet medical need. NeuroSense Therapeutics Ltd. operates in the global biopharmaceutical market, where it contributes to the advancement of novel drug candidates through clinical and preclinical development. Based in Herzliya, Israel, the company is positioned within the specialized field of neuroscience-focused drug discovery and development.

CEO Mr. Alon Ben-Noon · 17 employees · Israel · https://www.neurosense-tx.com